Valneva SE American Depositary Shares (VALN)

FairStock Score: 22/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I start with the price: $5.56 on 2026-10-13 and a $451.8M market cap. Valneva is a specialty vaccine company with commercial products, including IXIARO, DUKORAL, and IXCHIQ/VLA1553, and 620 employees. But the financials tell a weak story. In the second quarter of fiscal 2026, revenue was $34.9M and net income was -$31.2M, an -89.31% net margin. Trailing free cash flow is -$58.0M, a -12.8% FCF yield. The balance sheet is stretched: debt-to-equity is 2.59, and the Altman Z-score is -1.56. Returns are negative: ROE is -117.85% and ROCE is -16.68%. FairStock's P/E is -2.70, so there is no earnings anchor, and P/B is 5.62 at that close. For a loss-making business with negative returns, 5.62 times book does not scream value to me. Piotroski 5/9 is middling, while the FairStock score is 22/100 and the Lynch category is none because there are only 0 years of filed results, needing 3. A vaccine franchise can have a moat through approvals, manufacturing, and public-health relationships, but a moat only matters if it produces cash. Here cash is going out. Graham would want a margin of safety in assets or earnings; I see little visible margin of safety. Buffett would ask whether the competitive advantage is durable and whether the pipeline can be funded without dilution. Until revenue stabilizes and cash flow turns, this looks like a speculative bet on vaccine science rather than a value investment.

In plain English: Valneva makes vaccines for infectious diseases such as Japanese encephalitis and cholera. The business looks weak right now: it is losing money, burning cash, and carrying a lot of debt. At the October 13, 2026 close of $5.56, the price looks expensive against those weak numbers rather than cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer